ACE-031: Research Profile, Dosages & Supplier Prices

Growth factor research · Lyophilized powder · Also known as: ACVR2B-Fc, soluble activin receptor type IIB, Ramatercept-class

ACE-031 is a growth factor research compound with a molecular weight of ~90-100 kDa (dimer) and a research half-life of ~10-14 days (fc-fusion). ACE-031 is a recombinant fusion protein combining the extracellular domain of the activin receptor type IIB (ActRIIB) with the Fc region of human IgG1. It acts as a soluble decoy receptor, capturing myostatin, activins and other TGF-beta ligands before they can signal through cell-surface receptors. It was developed by Acceleron Pharma and reached Phase 2 trials in Duchenne muscular dystrophy before development was halted.

Research Use Only (RUO). Not for human or veterinary use. Not medical advice.

Sequence	Recombinant fusion: extracellular domain of human ActRIIB linked to human IgG1 Fc
Formula	Protein fusion construct
Mol. weight	~90-100 kDa (dimer)
Half-life	~10-14 days (Fc-fusion)
Forms sold	Lyophilized powder

What is ACE-031?

In clinical research ACE-031 produced clear increases in lean body mass and thigh muscle volume after a single dose, validating the ligand-trap approach to myostatin pathway inhibition. The Fc fusion gives it an antibody-like half-life of around two weeks - completely unlike short-lived peptides. It remains an important reference compound in muscle-wasting research, and its trial data is frequently cited when evaluating newer ActRIIB pathway agents such as bimagrumab.

Mechanism of Action (Research Context)

Soluble ligand trap: the ActRIIB extracellular domain binds myostatin (GDF-8), activins A/B and GDF-11 with high affinity, preventing ActRIIB/ALK4-5 receptor activation and SMAD2/3 signaling. The IgG1 Fc domain confers extended circulation via FcRn recycling.

Research Areas

Myostatin pathway inhibitionMuscular dystrophy modelsMuscle wasting / cachexia researchTGF-beta ligand trap pharmacology

ACE-031 Dosages in Research

1mg vials (research reagent)

Clinical trials dosed 0.02-3 mg/kg subcutaneously with effects lasting weeks. Research-context only; development was discontinued after Phase 2.

Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.

Storage & Handling

Lyophilized: -20C or colder. Reconstituted: 2-8C, use within days; Fc-fusion proteins are aggregation-prone - handle gently, avoid freeze-thaw.

ACE-031 Supplier Price Comparison

No tracked suppliers stock ACE-031 yet — inventory syncs run continuously. Check our supplier reviews.

ACE-031 FAQ

Yes - it completed Phase 1 and Phase 2 trials in healthy volunteers and Duchenne muscular dystrophy patients, showing significant lean mass increases. Development was discontinued, partly due to minor vascular adverse events.

Both neutralize myostatin-family ligands, but ACE-031 is an engineered receptor-Fc decoy with a ~2 week half-life, while follistatin is a natural binding protein with shorter persistence. ACE-031 also captures a broader ligand set including GDF-11 and activins.

Technically it is a large recombinant fusion protein (~90-100 kDa dimer), not a synthetic peptide. It is grouped with peptide research compounds because it targets the same myostatin/activin pathway.

Age & Use Verification